Semaglutide, Omega-3s, and Diet Shift Next-Generation Epigenetic Aging Clocks in Human Studies
核心洞察
A systematic review of 41 human studies identifies interventions including semaglutide, omega-3 fatty acids (搜索), plant-rich diets, exercise, pitavastatin, and caloric restriction that favorably shift next-generation DNA methylation-based epigenetic aging clocks.
Emtricitabine-tenofovir-alafenamide (搜索) produced the largest effect, reducing DNAm PhenoAge by more than 6 years, while semaglutide showed the greatest impact on slowing biological aging speed.
The authors caution that next-generation clocks remain investigational biomarkers and clock changes do not yet prove clinical age reversal or improved long-term outcomes.
A comprehensive systematic review published in Frontiers in Genetics has mapped 41 human studies to identify which interventions can shift next-generation DNA methylation-based epigenetic aging clocks—powerful machine-learning tools trained to predict biological aging, mortality risk, and healthspan rather than simply chronological age.
The review, conducted by Adiv Johnson from Tally Health (搜索) and David Sinclair from Harvard Medical School, systematically searched the literature for studies reporting the effects of various interventions on at least one next-generation epigenetic clock. The resulting evidence map, made publicly available alongside supplementary tables via a Frontiers/figshare dataset, highlights both promising interventions and critical gaps in the current evidence base.
Pharmaceutical Interventions Show Significant Clock Shifts
Among pharmaceutical agents, several produced statistically significant changes in next-generation clock outputs. A 12-week course of emtricitabine-tenofovir-alafenamide (搜索), an antiviral combination medication, reduced several epigenetic clock outputs in healthy individuals without HIV—including a reduction in DNAm PhenoAge by more than 6 years, the largest magnitude effect observed across all interventions. However, the same treatment also reduced AdaptAge, a clock intended to capture beneficial adaptive changes, underscoring the complexity of interpreting these biomarkers.
Semaglutide, a GLP-1 receptor agonist, administered over 32 weeks reduced a range of next-generation epigenetic aging clocks predicting clock-estimated biological age and aging speed in patients with HIV-related lipohypertrophy (搜索). Notably, semaglutide demonstrated the greatest impact on slowing biological aging speed among all interventions analyzed and also showed a second large effect on Systems Age.
Other pharmaceutical findings included a reduction in OMICmAge following 2–3 weeks of ketamine infusions in patients with major depressive disorder (搜索) or post-traumatic stress disorder (搜索), though other initially significant clock changes did not remain significant after correction. Two years of pitavastatin treatment in patients with HIV infection (搜索) significantly reduced DunedinPACE, a clock measuring the pace of biological aging.
Lifestyle and Dietary Interventions
The review identified several lifestyle and supplementation approaches associated with favorable clock changes. A 6-week supplementation with omega-3 fatty acids (搜索) reduced epigenetic clocks reflecting harmful age-related changes and increased clocks reflecting protective, adaptive changes in overweight individuals. Two years of multivitamin-multimineral supplementation reduced two PC-based epigenetic clock measures reflecting clock-predicted biological age and mortality risk in healthy individuals.
A plant-rich diet similarly reduced epigenetic clock-predicted biological age and mortality risk in healthy individuals, though the physical activity arm alone did not produce significant changes. In non-obese individuals, a 2-year caloric restriction intervention reduced epigenetic clock-predicted biological aging speed.
Not all lifestyle approaches proved beneficial. One study found that supplementation combined with encouragement to walk and practice mindfulness actually increased DunedinPACE after one year.
Non-Pharmaceutical and Psychosocial Interventions
Among non-pharmaceutical clinical therapeutics, kidney transplantation reduced selected epigenetic aging measures in patients with chronic kidney disease (搜索), and umbilical cord plasma concentrate therapy reduced selected measures in healthy individuals. Conversely, plasmapheresis—the removal of plasma—increased selected epigenetic-age and aging-speed clock outputs in healthy individuals.
A 20-week internet-based training program for parent-child interaction reduced biological aging speed in young individuals with developmental delay, representing one of the few psychosocial interventions with a significant effect.
Non-Significant Findings and Mixed Results
The largest category of studies comprised interventions that failed to significantly alter epigenetic aging clocks. Metformin produced mixed results: while a 6-month treatment failed to improve clocks in overweight or obese breast cancer survivors, a 24-week treatment significantly reduced PC DNAm PhenoAge and PC GrimAge in individuals with virologically suppressed HIV and normal glucose. Other interventions yielding non-significant outcomes included green-based supplements, rapamycin, home-based exercise, certain antiretroviral therapy strategies, folic acid, and nicotinamide riboside.
Investigational Status and Future Directions
The authors and secondary coverage emphasize that next-generation epigenetic clocks remain investigational biomarkers and are not yet validated as clinical surrogate endpoints. "Clock changes do not by themselves prove clinical age reversal or improved long-term outcomes," the paper states. The reported effect sizes are model-derived estimates and do not directly translate into changes in whole-body biological aging or expected lifespan.
Future studies are needed to decode how these interventions modulate DNA methylation status to accelerate or decelerate epigenetic age estimates. Validation against age-related health outcomes will be essential before these clocks can be adopted as clinical surrogate endpoints. Recent advances in artificial intelligence have led to the development of more interpretable epigenetic clocks, which may improve the clinical applicability of these tools moving forward.